RNLXY
Renalytix plcCompany Information
- Company Name
- Renalytix plc
- CIK
- CIK0001811115
- Category
- <br>Emerging growth company
- Ticker: Exchange
- RNLXY: OTC, RENXF: OTC, RNLXD: OTC
- Fiscal Year End
- June 30
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 8071
- SIC Description
- Services-Medical Laboratories
- Ticker
- RNLXY
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- —
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2023-12-31
- Institutional shares owned
- 4,773,796
- Shares outstanding
- 1,945,361
- Ownership
- 245.39%
Earnings Market Reaction
- Filing date
- 2024-11-19
- Price on filing date
- —
- 1-month reaction
- 25.33%
- 3-month reaction
- 62.67%
Balance Sheet
Values in millions ($)| Line item | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||
| Cash And Cash Equivalents At Carrying Value | 1 | 5 | 5 | 6 | 14 | 25 | ||||||
| Accounts Receivable Net Current | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 2 | 1 | ||||||
| Assets Current | 3 | 6 | 6 | 8 | 16 | 27 | ||||||
| Notes And Loans Receivable Net Current | - | - | - | - | - | 0 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Investment Owned At Fair Value | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 5 | 8 | 9 | 11 | 20 | 31 | ||||||
| Investments In Affiliates Subsidiaries Associates And Joint Ventures | - | - | - | - | - | 0 | ||||||
Liabilities Current | ||||||||||||
| Accrued Liabilities Current | 2 | 3 | 4 | 4 | 5 | 7 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Convertible Notes Payable Current | 4 | 4 | 4 | 3 | 5 | 4 | ||||||
| Liabilities Current | 12 | 11 | 15 | 14 | 15 | 16 | ||||||
| Deferred Revenue Current | - | - | - | - | - | 0 | ||||||
| Convertible Long Term Notes Payable | 4 | 4 | 5 | 5 | 6 | 7 | ||||||
| Operating Lease Liability Noncurrent | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 16 | 16 | 20 | 19 | 21 | 24 | ||||||
Stockholders Equity | ||||||||||||
| Common Stock Value | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 207 | 205 | 195 | 190 | 188 | 186 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | -1 | -2 | -2 | -1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -217 | -212 | -205 | -197 | -188 | -178 | ||||||
| Stockholders Equity | -11 | -8 | -11 | -8 | -1 | 7 | ||||||
| Liabilities And Stockholders Equity | 5 | 8 | 9 | 11 | 20 | 31 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 3 | 3 | 3 | 2 | 2 | 3 | ||||||
| Common Stock Shares Issued | 3 | 3 | 2 | 2 | 2 | 2 | ||||||
| Shares Outstanding | 3 | 3 | 2 | 2 | 2 | 2 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialRenalytix plc (RNLXY) — SEC Financial Statements & Analysis
Renalytix plc (RNLXY) is a services-medical laboratories company, incorporated in X0. Renalytix plc trades on OTC as: RNLXY, RENXF, RNLXD. Renalytix plc (RNLXY)'s most recent SEC filing is a Form 10-Q for the period ended 2024-09-30, filed with the SEC on 2024-11-19. Based on that filing, Renalytix plc carries a market cap of $276.13M, a P/E ratio of -9.85x, a P/B ratio of -24.40x, a P/S ratio of 117.40x, an enterprise value of $283.47M, and an EV/EBITDA multiple of -11.56x. On profitability, it posts a gross margin of 12.71%, an operating margin of -1054.93%, a net margin of -1191.75%, a Return on Equity (ROE) of 437.63%, and a Return on Assets (ROA) of -230.38%. Per share, it reports EPS of $-13.26, diluted EPS of $-13.26, free cash flow per share of $-11.56, and a dividend per share of $0.00. On the balance sheet, it maintains a current ratio of 0.24x, a quick ratio of 0.15x, working capital of $-9.13M, a debt-to-equity ratio of -1.42x, a debt ratio of 3.36, free cash flow of $-24.44M (TTM), and net debt of $7.33M. Figures sourced from SEC EDGAR.
- Market Cap
- $276.13M
- P/E TTM
- -9.85x
- EPS TTM
- $-13.26
- P/B TTM
- -24.40x
- ROE TTM
- 437.63%
- ROA TTM
- -230.38%
- Debt To Equity
- -1.42x
- Free Cash Flow TTM
- $-24.44M
Data as of 2024-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Renalytix plc in?
Renalytix plc (RNLXY) operates in the Services-Medical Laboratories industry.
What exchange does RNLXY trade on?
Renalytix plc (RNLXY) trades on the OTC.
Where is Renalytix plc incorporated?
Renalytix plc is incorporated in United Kingdom.
When was Renalytix plc (RNLXY)'s most recent SEC filing?
Renalytix plc (RNLXY)'s most recent SEC filing is a Form 10-Q for the period ended 2024-09-30, filed with the SEC on 2024-11-19.
What is RNLXY's market cap?
Renalytix plc (RNLXY) has a market capitalization of $276.13M as of 2024-09-30.
What is RNLXY's EPS (earnings per share)?
Renalytix plc (RNLXY)'s trailing twelve month EPS is $-13.26 as of 2024-09-30.
What is RNLXY's ROE (return on equity)?
Renalytix plc (RNLXY)'s trailing twelve month Return on Equity (ROE) is 437.63% as of 2024-09-30.
What is RNLXY's ROA (return on assets)?
Renalytix plc (RNLXY)'s trailing twelve month Return on Assets (ROA) is -230.38% as of 2024-09-30.
What is RNLXY's EV/EBITDA?
Renalytix plc (RNLXY)'s trailing twelve month EV/EBITDA is -11.56x as of 2024-09-30.